LDS Technology Overview

At LDS, we’ve pioneered an exclusive and innovative platform delivery technology capable of handling a diverse range of active molecules, including those with poor solubility and permeability (Class III and IV as per the BCS classification). 

Our technology finds applications across various industries, including pharmaceuticals, nutraceuticals, and cosmeceuticals, offering versatile delivery methods such as creams, softgels, sprays, gels, and viscous or non-viscous solutions to suit different needs. 

Comprising lipid-based, safe, and non-toxic ingredients infused with specialized “membrane recognition” and “permeation agents,” our flexible structures serve as carriers for both small and large active molecules, ensuring enhanced bioavailability. 

Our technology stands out for its cost-effectiveness, ease of production, and stability across a wide range of temperatures and conditions.

We Use the Most Sophisticated and Advanced Equipment

We have access to state-of-the-art analytical tools, both in our in-house laboratories and at the Nano-Center at the University. These tools enable us to thoroughly characterize and understand the nano-domain structures and their properties at every stage, from development to post-production.

Unique Structure That Enhances Delivery

The core technology at LDS is derived from innovative “molecular engineering models” that enable the formation of new types of modified nano-domains. These domains are “coronated” at their interface with “membrane recognition molecules” and “permeation agents,” facilitating the efficient transport of active molecules. 

These structures enable intimate contact with target tissue surfaces, promoting the diffusion of active molecules across membranes. 

Furthermore, the structures include components that allow the direct delivery of active molecules to the surface or membrane interface without the need for any intermediary.

Controlled Release at the Required Rate

LDS carefully selects precise ingredients to enable each nano-domain to solubilize a specific active molecule at the required loading capacity. The nature of the active molecule and its embedding at the interface of the nano-domains (rather than in their core) can be manipulated to achieve controlled release.

Chaotropic guest molecules
disordering the structure

Cosmotropic guest molecules increasing the order

How Does It Work?

The tailor-made ‘oily’ nano-domains are meticulously designed and prepared by loading active molecules either at the interface or within the core of the structures. These domains are coated with specific excipients that facilitate the permeation of active molecules across surfaces or membranes (permeating agents).

Once the nano-domains migrate to a membrane interface and recognize the delivery site, the structure adheres to the surface and allows the active molecule to be released via diffusion.

Migration of the Nano-Domains to the Membrane

The nano-domains identify and recognize the specific membrane surface to which they will adhere.

Adherence of the Nano-Domains to the Membrane

The nano-domains firmly adhere to the membrane surface, allowing the active molecule to be released through membrane undulation.

Permeation of Active Molecules Through the Membrane

The intimate contact between the nano-domains and the membrane facilitates the passive diffusion of active molecules across the membrane.

Departure of the Nano-Domains from the Membrane

Once the active molecules are delivered, the empty nano-domains detach from the membrane and are subsequently eliminated from the body.

Publications

Tehila Mishraki-Berkowitz Guy Cohen Abraham Aserin, N. Garti. Colloids Surfaces B, Biointerfaces 2018, 12;161: 670-676.

R.E. Hoffman, E. Darmon, A. Aserin, N. Garti, Part 1- Proof of concept. Journal of Colloid and Interface Science, 2016, 463, 349-357.

T. Mishraki-Berkowitz, P. Ben Ishai, A. Aserin, Yu. Feldman, N. Garti. Physical Chemistry Chemical Physics,2015, 17(14), 9499-9508.

M. Cohen-Avrahami, A. I. Shames2, M. F. Ottaviani3, A. Aserin, N. Garti, Colloids and Surfaces B. Biointerfaces, 2014, 122, 231-240.

V.L. Kolev, A.N. Ivanova, G.K. Madjarova, A. Aserin, N. Garti, Journal of Physical Chemistry B, 2014, 118(20), 5459-5470.

L. Bitan-Cherbakovsky, A. Aserin, N. Garti, Colloids and Surfaces, B: Biointerfaces ,2013, 112, 87-95.

T. Mishraki, P. Ben Ishai, D. Babukh, A. Aserin, Y. Feldman, N. Garti, Journal of Colloid and Interface Science; 396, 2013178-186.

M. Cohen-Avrahami, D. Libster, A. Aserin, N. Garti, Journal of Controlled Release,2012, 159(3), 419–428.

I. Amar-Yuli, J. Adamcik, S. Blau, A. Aserin, N. Garti, R. Mezzenga, Soft Matter ,2011, 7(18), 8162-8168.

J. Gurfinkel, A. Aserin, N. Garti, Colloids and Surfaces A: Physicochemical and Engineering Aspects ,2011, 392(1), 322-328. D. Libster, A. Aserin, N. Garti. Interactions of biomacromolecules with reverse hexagonal liquid crystals: Drug delivery and crystallization applications. Journal of Colloid and Interface Science ,2011, 356(2), 375-386.4.

L. Bitan-Cherbakovsky, D. Libster, A. Aserin, N. Garti, Journal of Physical Chemistry B, 2011, 115(42), 11984-11992.

R. Efrat, Z. Abramov, A. Aserin, N. Garti, Journal of Physical Chemistry B ,2010, 114(33), 10709-10716.

L. Bitan-Cherbakovsky, I. Yuli-Amar, A. Aserin, N. Garti, Langmuir,2010, 26(5), 3648-3653.

T. Mishraki, D. Libster, A. Aserin, N. Garti, Colloids Surf. B 2010, 75(2), 391-397.

Patents

Enclosed is a list of selected approved and filed patents related to LDS's new delivery technology.

Hexagonal systems for use in solubilizing, protecting and delivery of bio-macromolecule and/or active compounds.
Patents granted.

Mediums and methods for selective extraction of active compounds from plant material (including selective cannabinoids extraction).
Pending patent applications.
 

Solubilization in high loads of cannabinoids for fast and efficient delivery for oral applications
Pending patent applications.

Various novel nano-domains formulations for various administration routes of active compounds, including injectables, oral, topical formulations, etc.
Pending patent applications and granted patents.